Table of Contents
1
UI - 11494447
AU - Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoilova RS; Loginova IV;
TI -
Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
[Differential diagnostic and prognostic value of serum cytokines
(soluble CD30, soluble interleukin-2 receptor, interleukin-10 and
interleukin-6) in Hodgkin's disease and lymphosarcomas]
SO - Ter Arkh 2001;73(4):45-51
AIM: Determination of the importance of serum cytokines (sCD30, sIL-2R,
IL-10, IL-6) for diagnosis, response to chemotherapy and remission in
patients with lymphogranulomatosis and lymphosarcoma. MATERIAL AND
METHODS: Cytokine concentrations were measured in 87 samples of serum
(plasma) from 54 patients by ELISA. Diagnosis of Hodgkin's disease (HD)
and non-Hodgkin's lymphoma (NHL) was made histologically in 24 and 30
patients, respectively. RESULTS: The threshold concentrations of sCD30
(and less specific sIL-2R) for HD and NHL patients allowed to estimate
sensitivity to chemotherapy after the second course. The threshold
concentration of IL-10 can distinguish HD from NHL. Changes in IL-6
concentrations were nonspecific. CONCLUSION: On the basis of the
threshold concentrations of sCD30 and IL-10 we offer the scheme of
lymphoma diagnosis and prediction of the disease sensitivity to
chemotherapy which reduce the duration of lymphoma restaging.
2
UI - 11409315
AU - Lalic H; Radosevic-Stasic B; Volavsek C
TI -
High incidence of chromosome aberrations after radiochemotherapy for
Hodgkin's disease: a report of a case and a review of the literature.
SO - Folia Biol (Praha) 2001;47(3):101-5
AD - Department of Occupational and Environmental Medicine, Medical Faculty,
University of Rijeka, Croatia. biserr@mamed.medri.hr
To emphasize the importance of information obtained by conventional
cytogenetic tests, in this study we will present a case report showing
the development of HD in a young engineer of medical radiology, who had
been professionally exposed to ionizing radiation during 4 years.
Bio-dosimeter data and chromosomal aberration analysis made in a group
of colleagues working in the same ionizing conditions excluded the
possibility that she was overexposed to ionizing radiation, but
retroactive analysis showed that at the time of employment she had a
moderately increased level of chromosomal aberrations in peripheral
blood lymphocytes (4.6%), with higher than normal incidence of chromatid
breaks (22 x 10(-3) per cell) and dicentric fragments (5 x 10(-3) per
cell). After the treatment of lymphoma by chemotherapy in combination
with radiotherapy she also demonstrated a very high post-therapeutic
level of chromosomal aberrations (21.5%), which consisted mostly of
increased dicentric fragments (65 x 10(-3) per cell). Although her
illness is now clinically cured, the observed genotoxic changes point to
a greater risk for delayed complications after HD, emphasizing the
necessity for further continuous survey of this patient.
3
UI - 11474574
AU - Kuppers R; Sousa AB; Baur AS; Strickler JG; Rajewsky K; Hansmann ML
TI -
Common germinal-center B-cell origin of the malignant cells in two
composite lymphomas, involving classical Hodgkin's disease and either
follicular lymphoma or B-CLL.
SO - Mol Med 2001 May;7(5):285-92
AD - Institute for Genetics, University of Cologne, Germany.
rkuppers@mac.genetik.uni-koeln.de
BACKGROUND: Classical Hodgkin's disease (HD) and B-cell non-Hodgkin
lymphoma (NHL) occasionally occur in the same patient. Such composite
lymphomas represent interesting models to study the pathogenesis of
B-cell lymphomas and the relationship between HD and B-cell NHL.
MATERIALS AND METHODS: We analyzed two composite lymphomas (a
combination of classical HD with follicular lymphoma [FL] and a
combination of classical HD with B-cell chronic lymphocytic leukemia
[B-CLL]) by micromanipulation of single cells from tissue sections and
amplification of immunoglobulin V region genes for the clonal
relationship of the tumor cells. RESULTS: In both cases, clonally
related variable (V) genes with both shared as well as distinct somatic
mutations were obtained from the two lymphomas, showing that in each of
the cases the distinct tumor cells were members of a common germinal
center (GC) B-cell clone. FL cells from two different lymph nodes of
patient 1 showed a similar mutation pattern, suggesting that
infiltration of these lymph nodes by tumor cells was not restricted to a
particular FL cell or subclone. In the FL, a single cell was identified
with a mutation signature indicating that premalignant cells can persist
in the tissue. CONCLUSIONS: The cases presented here further underline
the close relationship between HD and B-cell NHL and the role of the GC
in lymphomagenesis. Whereas the latter was already suggested for FL and
HD, the present study indicates that also in the B-CLL subset
characterized by mutated Ig genes, important steps in malignant
transformation happen in the GC, and that HRS cells can derive from
CD5-positive B cells.
4
UI - 11414479
AU - Brown HG; Whiting DM; Prostko ER; Fox KR; Zhang J
TI -
SO - Brain Pathol 2001 Jul;11(3):387-8; 393
AD - Allegheny General Hospital, Pittsburgh PA, USA.
The January Cases of the Month (COM): A case of intracranial metastatic
nodular sclerosing Hodgkin's disease without dural attachment in a
37-year-old previously stage III male is presented with a brief review
of the literature. Both the primary tumor in the lymph node biopsy and
the metastatic brain tumor showed similar histopathology and a
immunohistochemical profile typical for Hodgkin's Disease. After
chemotherapy, there are no signs of recurrence or systemic disease on
follow-up for five months.
5
UI - 11410412
AU - Canales MA; Fernandez-Jimenez MC; Martin A; Arrieta R; Caballero MD;
TI -
Diez J; Quevedo E; Garcia-Bustos J; San Miguel JF; Hernandez-Navarro F
Identification of factors associated with poor peripheral blood
progenitor cell mobilization in Hodgkin's disease.
SO - Haematologica 2001 May;86(5):494-8
AD - Servicio de Hematologia, Hospital Universitario La Paz, Paseo de la
Castellana 261, 28046 Madrid, Spain. canalesmiguel@hotmail.com
BACKGROUND AND OBJECTIVES. Although the use of drugs which damage stem
cells is common in patients with Hodgkin's disease (HD), factors
affecting peripheral blood progenitor cell (PBPC) mobilization have not
been clearly established in this group of patients. The aim of this
study was to identify factors associated with poor PBPC mobilization in
patients with HD. DESIGN AND METHODS.In order to address this issue we
have evaluated in 54 patients with HD mobilized with G-CSF alone the
following factors: sex, age, histologic subtype, B symptoms at
diagnosis, status of remission, previous chemotherapy and radiotherapy,
interval from diagnosis and last chemotherapy cycle to harvest, and dose
of G-CSF. Univariate analysis was performed using Student's t-test,
Pearson's correlation and Spearman's correlation. A stepwise regression
model was used to determine which of the variables was the most
predictive of PBPC mobilization. RESULTS. In univariate analysis poorer
PBPC mobilization was observed in patients who had previously received
at least two courses of mini-BEAM (p=0.006), a high number of different
chemotherapy regimens (p=0.002), a chemotherapy score >30 (p=0.02) and
more than 9 months of alkylating agents (p=0.07). We did not find
radiotherapy to be a significant factor affecting progenitor cell yield
(p=0.59). In the stepwise regression model, only the previous
administration of two or more mini-BEAM cycles predicted a poor PBPC
yield (p=0.006). INTERPRETATION AND CONCLUSIONS. Previous chemotherapy,
principally exposure to a mini-BEAM regimen, seems to be the principal
factor affecting collection of PBPC in patients with HD mobilized with
G-CSF alone. Since mini-BEAM is an effective salvage regimen in relapsed
or refractory HD, collection of PBPC should be planned when there has
been no or only minimal exposure to a mini-BEAM regimen.
6
UI - 11412652
AU - Navarro B; Yebra M; Romero J; Suarez-Massa D
TI -
[Hodgkin lymphoma associated with primary Sjogren's syndrome]
SO - Med Clin (Barc) 2001 May 5;116(16):636
7
UI - 11456228
AU - Stagnaro E; Ramazzotti V; Crosignani P; Fontana A; Masala G; Miligi L;
TI -
Nanni O; Neri M; Rodella S; Costantini AS; Tumino R; Vigano C; Vindigni
C; Vineis P
Smoking and hematolymphopoietic malignancies.
SO - Cancer Causes Control 2001 May;12(4):325-34
AD - Epidemiology Unit of National Cancer Research Institute, Genoa, Italy.
stagnaro@hp380.ist.unige.it
OBJECTIVE: Tobacco use is the most prominent cause of respiratory
cancers. Little is known, however, about the influence of smoking on
hematolymphopoietic malignancies. To evaluate this relation, a
population-based case-control study was carried out in 12 areas of
Italy. METHODS: Detailed interviews on tobacco smoking habits were
administered to 1450 non-Hodgkin's lymphoma (NHL), 365 Hodgkin's disease
(HD), 270 multiple myeloma (MM), and 649 leukemia (LEU) patients
occurring from 1990 to 1993, and 1779 population controls. RESULTS: We
found a slightly increased risk for NHL in smokers (odds ratio 1.2, 95%
confidence interval 1.0-1.4 for ever smokers), but a consistent positive
association was shown only for follicular NHL. In this subtype, a
significant excess risk was observed for ever versus never smokers,
after adjustment for gender, age, geographic residence, education, and
respondent (OR = 1.8, 95%, CI 1.3-2.7), with a positive
exposure-response gradient for smoking duration (p < 0.01). The risk for
follicular NHL was significantly elevated only among women, with ever
smokers showing OR = 2.3 (CI 1.4-3.8), while for men we found OR = 1.3
(CI 0.69-2.3). No major differences were shown according to age. Female
subjects also showed significant positive exposure-response trends for
duration. CONCLUSION: Cigarette smoking could be a risk factor for
follicular NHL among women. For HD, MM, or LEU, no clear association was
observed.
8
UI - 11488851
AU - Hepburn MD; Nagesh K; Heppleston AD; Cachia PG; Pippard MJ
TI -
Timing of the appearance of multipotential and committed haemopoietic
progenitors in peripheral blood after mobilization in patients with
lymphoma.
SO - Clin Lab Haematol 2001 Apr;23(2):119-24
AD - Department of Molecular and Cellular Pathology, Ninewells Hospital and
Medical School, University of Dundee, Dundee, DD1 9SY, Scotland, UK.
mary.hepburn@tuht.scot.nhs.uk
The pattern of emergence of multipotential (CFU-A) and committed (CFU-GM
and BFU-E) progenitor cells in peripheral blood has been examined in
patients with Hodgkin's disease and non-Hodgkin's lymphoma. Mobilization
protocols used chemotherapy with or without granulocyte
colony-stimulating factor (n=8 and n=5, respectively). In all patients,
the numbers of CFU-A, CFU-GM and BFU-E peaked simultaneously, rather
than sequentially, suggesting that marrow regeneration after these
mobilization protocols occurred from progenitors at all stages of
differentiation. We conclude that peripheral blood stem cell harvest
strategies based on peak values for total progenitor numbers will also
capture maximum numbers of multipotential progenitors. However, the
variable relationship between CFU-A and CFU-GM numbers suggests that
overall progenitor cell numbers can give only a broad estimate of the
absolute numbers of multipotential progenitors in an individual harvest.
9
UI - 11039518
AU - Kharfan Dabaja MA; Morgensztern D; Markoe AM; Bartlett-Pandite L
TI -
Radiation recall dermatitis induced by methotrexate in a patient with
Hodgkin's disease.
SO - Am J Clin Oncol 2000 Oct;23(5):531-3
AD - Division of Hematology-Oncology, University of Miami/Jackson Memorial
Hospital, Florida, USA.
Radiation recall dermatitis refers to an inflammatory skin reaction at a
previously irradiated field subsequent to chemotherapy administration. A
number of antineoplastic agents have been reported to cause this
phenomenon. We observed radiation recall dermatitis in a patient with
stage IV nodular sclerosing Hodgkin's disease after methotrexate therapy
for acute graft-versus-host disease (GVHD) prophylaxis. The patient had
previously undergone matched related bone marrow transplantation with
busulfan and cyclophosphamide as a preparative regimen. Subsequently,
she received cyclosporine and methotrexate for acute GVHD prophylaxis.
Two areas of skin previously irradiated to 3,000 cGy developed radiation
recall dermatitis after two doses of methotrexate given 2 days apart and
exacerbated by the third and fourth doses. This reaction occurred 34
days after the last dose of radiation therapy (RT). We believe this is
the first case of radiation recall dermatitis after methotrexate
therapy. Given the increased use of methotrexate in several neoadjuvant
and adjuvant protocols in association with RT, its potential to produce
radiation recall reactions should be considered.
10
UI - 11510193
AU - Fomina IG; Marinin VF; Solomatin AS; Makhnach GK; Shibeko EA
TI -
[Respiratory syndrome masking lymphogranulomatosis]
SO - Klin Med (Mosk) 2001;79(5):61-3
11
UI - 11521372
AU - Shevchenko IuL; Bobrov LL; Novik AA; Obrazan AG; Krysiuk OB
TI -
[Altered left ventricular diastolic function in patients with
lymphogranulomatosis]
SO - Klin Med (Mosk) 2001;79(6):20-3
Impaired elastic characteristics of the left heart ventricle and
restructuring of its diastolic bloodflow were revealed in 28 patients
with Hodgkin's disease by complex Doppler echocardiographic study of
intracardiac hemodynamics. The most pronounced disorders of the
diastolic function were detected in patients with pericardial
involvement. More pronounced tumor intoxication in patients with
mixed-cell variant of the tumor resulted in remodeling of the left
ventricle, left atrial dysfunction, and restructuring of the diastolic
bloodflow, which indicated combined impairment of the left ventricular
diastolic relaxation and left atrial contractility. Chemotherapy
augmented disorders in diastolic bloodflow, the increase in the number
of polychemotherapy courses being associated with a trend to
deterioration of left-ventricular relaxation. Hence, tumor intoxication
and drug cardiotoxicity determine the formation of central hemodynamic
disorders, one of whose principal components is diastolic dysfunction of
the left heart ventricle.
12
UI - 11512599
AU - Dowling AJ; Prince HM; Wirth A; Wolf M; Januszewicz EH; Juneja S;
TI -
Seymour JF; Gates P; Smith JG
High-dose therapy and autologous transplantation for lymphoma: The Peter
MacCallum Cancer Institute experience.
SO - Intern Med J 2001 Jul;31(5):279-89
AD - Department of Medical Oncology, St Vincent's Hospital, Melbourne,
Victoria, Australia.
BACKGROUND: High-dose therapy (HDT) with autologous bone marrow or blood
cell transplantation for the treatment of lymphoma commenced at Peter
MacCallum Cancer Institute in 1986. AIM: To examine the patient
characteristics and outcomes of patients with non-Hodgkin's lymphoma
(NHL) and Hodgkin's disease (HD) treated with HDT and autologous
transplantation at our Institute in the first 10 years of the service
(1986-95). METHODS: A retrospective analysis was performed examining
patient characteristics, prior chemotherapy regimens, pretransplant
disease status, HDT regimen, source of stem cells, time for
haematopoietic recovery, complications of transplantation, response
rates, overall survival (OS) and progression-free survival (PFS).
RESULTS: Sixty-seven patients with NHL were treated with an estimated
5-year OS rate of 44% (95% confidence interval (CI) 32-56%) and PFS rate
of 34% (95% CI 21-44%). Factors independently predictive of an
unfavourable PFS on multivariate analyses were presence of
constitutional symptoms at transplant (P < 0.002) and
chemotherapy-resistant disease at transplant (P = 0.02). Twenty-three
patients with HD were treated with a 5-year predicted OS rate of 74%
(95% CI 56-92%) and PFS rate of 57% (95% CI 36-77%). There was no
difference in PFS for HD patients who relapsed either within 12 months
of completion of front-line therapy or after this time (P= 0.5). The
transplant-related mortality for the entire cohort was 17%, with a
progressive decrease over time. CONCLUSION: HDT with autologous
transplantation achieves durable PFS and OS in patients with lymphoma.
Improved patient selection, therapy modifications according to
prognostic factors and ongoing improvements in supportive care should
improve outcomes further.
13
UI - 11525910
AU - Bilban-Jakopin C; Bilban M
TI -
Genotoxic effects of radiotherapy and chemotherapy on circulating
lymphocytes in patients with Hodgkin's disease.
SO - Mutat Res 2001 Oct 18;497(1-2):81-8
AD - Department of Radiation Oncology, Institute of Oncology, SI-1000
Ljubljana, 2, Zaloska, Slovenia. cjakopin@onko-i.si
PURPOSE: The aim of this study was to find out the structural
chromosomal changes in somatic cells after chemotherapy (CT) with or
without radiotherapy (RT). METHODS AND MATERIALS: This prospective study
included 30 Hodgkin's disease (HD) patients. The patients of Group I(1)
had only MOPP/ABV CT. The patients of Group II(2) also had irradiation.
Group III(3) (control group) consisted of healthy subjects without any
reported malignant disease. Mutagenetic testing was performed at the
time of diagnosis and was repeated immediately after treatment and again
6 months later. The following tests were applied: structural chromosomal
aberrations (CA), sister chromatid exchange (SCE) and micronucleus (MN)
tests. RESULTS: Prior to treatment, the chromosome damage in our
patients was not higher than that in the control group.Immediately after
the complete treatment, we observed a strong inhibition of the mitotic
activity of lymphocytes as well as a significant increase in the
frequency of CA, MN and SCE in the Groups I and II. In patients treated
by RT, we found statistically significant differences between the Groups
I and II in MN (P<0.005) and CA frequencies (P<0.005), and an increased
number of dicentrics (P=0.021). Six months after the complete treatment,
the mitotic activity was found to be nearly normal, but chromosome
damage occurred. CA and SCE values did not differ much from the values
measured immediately after treatment, whereas MN values decreased
without returning to the baseline levels. The chromosome damage
persisted even 6 months after combined RT and CT. The damage in the
genome of individual cells was in some cases even greater than
immediately after treatment. The possible risk of neoplastic
transformation posed by these heavily damaged cells, if viable, due to
the changes in the expression of oncogenes or tumour suppresser genes,
is discussed.
14
UI - 11573286
AU - Abe M
TI -
[Cellular origin of human B-cell neoplasms and Hodgkin's disease based
on analysis of somatic hypermutations in the immunoglobulin variable
region genes]
SO - Rinsho Byori 2001 Aug;49(8):779-87
AD - 1st Department of Pathology, School of Medicine, Fukushima Medical
University, Fukushima 960-1295.
In response to antigen stimulation, B cells undergo a germinal
center(GC) reaction such as somatic hypermutations of the immunoglobulin
variable region genes, which results in the production and selection of
antigen-specific antibodies with increased affinity. Therefore, somatic
hypermutations are considered to be a hallmark of GC B cells and their
descendants. Pre-GC B cells(precursor B cells, immature B cells, naive B
cells and CD5+ B cells) carry no somatic hypermutations, whereas GC B
cells and post-GC B cells(memory B cells and plasma cells) express
somatic hypermutations. This phenomenon is useful in identifying the
cellular origin of various B-cell neoplasms. Precursor B-lymphoblastic
leukemia/lymphoma, mantle cell lymphoma, and most B-CLL originate from
pre-GC B cells, and follicular lymphoma, Burkitt's lymphoma, marginal
zone B-cell lymphoma, diffuse large B-cell lymphoma and myeloma from GC
B cells or post-GC B cells. Nodular lymphocyte-predominant Hodgkin's
disease and most classical types of Hodgkin's disease are derived from
GC B cells. Most human-B cell neoplasms including Hodgkin's disease are
derived from GC B cells or their descendants. Molecular processes that
modify the DNA of GC B cells, such as somatic hypermutation, class
switching and receptor editing occur in the environment of the GCs, and
increase the risk of malignant transformation.
15
UI - 11577129
AU - Caussinus E; Meggetto F; Delsol G; Brousset P
TI -
Simultaneous occurrence of Epstein-Barr virus associated Hodgkin's
disease and HHV-8 related multicentric Castleman's disease: a fortuitous
event?
SO - J Clin Pathol 2001 Oct;54(10):790-1
AD - Laboratoire d'Anatomie Pathologique and CNRS-CIGH, UPR8291, CHU Purpan,
Place du Dr Baylac, 31059 Toulouse, France.
Previous serological or molecular studies by means of the polymerase
chain reaction have failed to show an association between classic
Hodgkin's disease (HD) and human herpesvirus 8 (HHV-8). Using
immunohistochemistry, this study re-examines (with anti-LNA1 antibody)
the possible association of HHV-8 with HD, particularly in human
immunodeficiency virus (HIV) infected patients. HHV-8 was not detected
in the Reed Sternberg cells of the cases examined (33 HIV negative and
17 HIV positive), thus confirming the lack of involvement of HHV-8 in
HD. Interestingly, a case of HHV-8 positive multicentric Castleman's
disease was associated with Epstein-Barr virus positive HD in the same
lymph node, which was probably a fortuitous occurrence.
16
UI - 11601255
AU - Zhao G; Boysen CD; Brown EF; Hassanein KM; Holmes FF; Holmes GE
TI -
Very long survival in pediatric cancer between 1944 and 1993.
SO - Chin Med J (Engl) 1999 Jul;112(7):615-9
AD - Henan Institute of Medical Sciences, Henan Medical University, Henan
450052, China.
OBJECTIVE: To identify factors associated with very long survival among
all cancer cases diagnosed at age 19 years or younger registered by the
Cancer Data Service at the University of Kansas Medical Center in Kansas
City, Kansas, U.S.A. in the 40-year period between 1944 and 1983, with
follow-up to 1993. METHODS: There were 2720 pediatric patients with 2750
cancers who were studied. Forty-four types of cancer were grouped into
11 diagnostic categories. Diagnosis years spanned four eras: 1944-1953,
1954-1963, 1964-1973, and 1974-1983. Cases were compared using specific
characteristics and were divided into short-term and long-term survivors
with the division generously set at seven years. The proportions of the
long-term survivors were compared by specific characteristics. RESULTS:
Among the diagnostic categories, leukemias were the most common (29.8%),
followed by CNS tumors (15.2%), and Hodgkin's disease (9.0%). Male to
female ratio was 4:3; average age at diagnosis was 8.83 +/- 6.08 years.
Long-term survivors totaled 1148 (41.7%). Prognosis was better in cases
diagnosed in earlier stages and in later eras. Proportion of long-term
survivors increased from 18.7% in era I to 52.6% in era IV. Improvement
of survival was statistically significant in most diagnostic categories.
CONCLUSIONS: This study shows continuing improvement of survival during
four consecutive eras for childhood and adolescent cancer. Early
diagnosis was associated with better survival. Unstaged cases decreased
over time reflecting progress in diagnostic techniques. Many patients
died before seven years after diagnosis. Those who survived more than
seven years had excellent survival. Pediatricians can expect to
participate in the care of these patients long after the original
dianosis and treatment.
17
UI - 11601211
AU - Deng F; Liu X; Tang W
TI -
[A clinicopathological study of nodular lymphocyte predominance
Hodgkin's disease]
SO - Zhonghua Xue Ye Xue Za Zhi 1999 May;20(5):239-41
AD - Department of Pathology, Zunyi Medical College, Zunyi 563003.
OBJECTIVE: To investigate the clinicopathological characteristics of
nodular lymphocyte predominance Hodgkin's disease. METHODS: Eleven
samples of paraffin embedded lymph node and one of frozen lymph node
from nodular lymphocyte predominance Hodgkin's disease patients were
studied. HE staining, immunohistochemistry for CD3, CD19, CD20, CD30,
CD45RB, kappa and lambda light chain and single L&H cell polymerase
chain reaction (PCR) were performed. RESULTS: The diagnosis of nodular
lymphocyte predominance Hodgkin's disease was established by the
identification of characteristic L&H cells in the nodular small
lymphocytes and histiocytes background. L&H cells expressed CD19(10/12),
CD20(12/12), CD45RB(12/12) and kappa light chain (11/12). IgH and V
kappa 4 family gene rearrangements were detected in the single L&H cell.
Eight of the patients survived more than 5 years. CONCLUSION: Nodular
lymphocyte predominance Hodgkin's disease has a very slow disease course
and a better prognosis. It is a malignant lymphoma derived from B cells.
18
UI - 11669022
AU - Kolar Z; Murray P; Ehrmann J Jr; Rihakova P; Constandinou C; Scott K;
TI -
Vojtesek R; Keily AM; Kod'ousek R
[Apoptosis of H/RS cells in relation to expression of cell cycle
proteins and EBV infection in patients with malignant lymphogranuloma]
SO - Cesk Patol 2001 Jul;37(3):123-4
AD - Ustav patologie LF UP, Hnevotinska 3, 775 15 Olomouc.
19
UI - 11669023
AU - Macak J; Habanec B; Fabian P
TI -
[Detection of Epstein-Barr virus in Hodgkin's disease]
SO - Cesk Patol 2001 Jul;37(3):124-5
AD - Ustav patologie Lekarske fakulty UP v Olomouci.
20
UI - 11602163
AU - Fuentes Pradera J; Arriola Arellano E; Miguel Cisneros J; Quiroga E
TI -
[Mediastinal adenopathies and pulmonary cavitated mass as onset form of
Hodgkin's disease]
SO - Med Clin (Barc) 2001 Oct 6;117(10):398-9
AD - Oncologia Medica. Hospitales Universitarios Virgen del Rocio. Sevilla.
21
UI - 11605073
AU - Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A;
TI -
Bares R; Claussen CD; Kanz L; Bokemeyer C
Comparison of 18FDG-PET with CT scans in the evaluation of patients with
residual and recurrent Hodgkin's lymphoma.
SO - Oncol Rep 2001 Nov-Dec;8(6):1393-9
AD - Department of Nuclear Medicine, University of Tuebingen, Tuebingen,
Germany.
The reliable assessment of residual masses after treatment as well as of
new lesions suspected for relapse remains a diagnostic problem in
patients with Hodgkin's disease (HD). The current study compares the
results obtained by CT scan to FDG-PET imaging in a blind analysis with
respect to the viability of residual masses and in case of suspected
relapse. Between 1/94 and 10/99, 47 comparisons of PET and corresponding
CT scans - 26 comparisons in 24 patients with residual tumors and 21
comparisons in 20 patients with suspected relapse of HD - were evaluated
by independent reviewers blinded to he results of each other. Patients
with primary diagnosis had been treated within trials of the German HD
Trial study group. Relapsed patients received intensified salvage
chemotherapy regimens. PET was assessed visually and by quantifying
glucose uptake (SUV). Changes in size of tumor lesions as well as
contrast medium enhancement served as criteria for assessment by CT
scans. Results were validated either by histologic examination of a
resected mass or biopsy (n=17) or by a clinical follow-up over 6 months
following treatment (n=30). In 26 cases with residual lesions FDG-PET
showed an increased tracer uptake in 8, 7 of which were true positive
(TP) and 1 false positive (FP). Eighteen cases were classified as being
negative (no viable HD), 17 true negative (TN) and 1 FN. In the blinded
reading of the corresponding CT scans, 10 cases with residual lesions
were considered to contain vital lymphoma (2 TP, 8 FP). Sixteen CT scans
were classified as negative (10 TP, 6 FN). The resulting sensitivity and
specificity of PET were 87.5% and 94.4% in contrast to only 25% and 56%
for CT scans. The positive and negative predictive values of PET and CT
scans were 87.5% and 94.4% and 20% and 62.5%, respectively. In patients
with suspected relapse, sensitivity and positive predictive value for
the diagnosis of the relapse were 100% and 86%, respectively, yielding
the same results for both methods. FDG-PET performed in HD patients with
residual masses appears to offer important additional information
regarding the presence of viable HD in these residual lesions. In
patients with suspected relapse of HD, FDG-PET seems not to offer any
information over CT scans. Using SUVs is not superior to visual
assessment of PET alone.
22
UI - 11673693
AU - Nabhan C; Krett N; Gandhi V; Rosen S
TI -
Gemcitabine in hematologic malignancies.
SO - Curr Opin Oncol 2001 Nov;13(6):514-21
AD - Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer
Center, Northwestern University Medical School, Chicago, Illinois 60611,
USA. c-nabhan@northwestern.edu
Gemcitabine is a pyrimidine analogue that showed significant activity in
solid malignancies. Gemcitabine acts by inhibiting DNA synthesis through
chain termination and ribonucleotide reductase inhibition. During
initial phase I and II studies, gemcitabine had a low toxicity profile
and was well tolerated as a single agent and in combination therapy.
Recently, there has been more interest in studying the activity of
gemcitabine in hematologic malignancies. Gemcitabine demonstrated good
activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma,
cutaneous T-cell lymphoma, and acute leukemias. There is a preponderance
of evidence on the activity of gemcitabine in vitro in myeloma and
leukemic cell lines. The activity of gemcitabine in these disorders will
pave the way for incorporating this agent into the early phases of
therapy.
23
UI - 11675352
AU - Fiumara P; Snell V; Li Y; Mukhopadhyay A; Younes M; Gillenwater AM;
TI -
Cabanillas F; Aggarwal BB; Younes A
Functional expression of receptor activator of nuclear factor kappaB in
Hodgkin disease cell lines.
SO - Blood 2001 Nov 1;98(9):2784-90
AD - Department of Lymphoma and Myeloma, Head and Neck Surgery, and
Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center,
Houston, TX 77030, USA.
The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease
(HD) express several members of the tumor necrosis factor (TNF) receptor
family, including CD30 and CD40, and secrete several cytokines and
chemokines. However, little is known about what regulates cytokine and
chemokine secretion in H/RS cells. Although H/RS cells are predominantly
of B-cell origin, they frequently share phenotypic and functional
features with dendritic cells (DCs). Previous studies reported that
receptor activator of nuclear factor kappaB (NF-kappaB) (RANK), a member
of the TNF receptor family, is expressed on DCs, and that RANK ligand
(RANKL) enhances DC survival and induces them to secrete cytokines. This
study reports that, similar to DCs, cultured H/RS cells expressed RANK.
However, unlike DCs, H/RS cells also expressed RANKL. Soluble RANKL
activated NF-kappaB and induced messenger RNA expression of
interferon-gamma, interleukin-8 (IL-8), IL-13, IL-9, IL-15, and RANTES,
in addition to the receptors for IL-9, IL-13, IL-15, and CCR4. RANKL
increased IL-8 and IL-13 levels in the supernatants of H/RS cell lines,
an effect that was blocked by soluble RANK. Furthermore, soluble RANK
decreased the basal level of IL-8 in one cell line, suggesting that IL-8
was induced by an autocrine RANKL/RANK loop. RANKL had no effect on H/RS
cell survival in culture, and it did not modulate the expression of
bcl-2, bcl-xL, bax, or inhibitors of apoptosis proteins. These data
provide evidence of further functional similarities between DCs and H/RS
cells. The coexpression of RANK and RANKL in H/RS cells suggests that
they may regulate cytokine and chemokine secretion in H/RS cells by an
autocrine mechanism.
24
UI - 11675520
AU - Stokoe CT; Ogden J; Jain VK
TI -
Activity of infusional etoposide, vincristine, and doxorubicin with
bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease.
SO - Oncologist 2001;6(5):428-34
AD - Baylor-Sammons Cancer Center, Dallas, Texas 75246, USA.
INTRODUCTION: A phase II study of EPOCH chemotherapy in relapsed
Hodgkin's disease was performed in 14 patients in a multicenter
community setting. Patients and Methods. A total of 14 patients (9 males
and 5 females) were included in the study. Ages ranged from 21-72 with a
median age of 33. Eleven out of 14 patients had advanced (stage III or
IV) disease, but all patients had good performance status. All 14
patients had received prior chemotherapy with ABVD, MOPP, or MOPP/ABVD
hybrid. RESULTS: A total of 57 cycles of EPOCH were administered during
this trial. Patients received a median of four cycles of chemotherapy.
An overall response rate of 86% was seen among the 14 patients with one
patient achieving a complete response. Following EPOCH chemotherapy, 7
of 12 patients who responded underwent high-dose chemotherapy with stem
cell support. Six out of 14 patients are currently alive, and three had
no evidence of disease at the time of last follow-up. Toxicity with
EPOCH chemotherapy consisted mainly of myelosuppression, and most
patients were managed on an outpatient basis. CONCLUSION: This
multicenter community study confirms the activity of EPOCH chemotherapy
in the treatment of patients with relapsed Hodgkin's disease.
25
UI - 11706423
AU - Laine PO; Lindqvist JC; Pyrhonen SO; Teerenhovi LM; Syrjanen SM; Meurman
TI -
JH
Lesions of the oral mucosa in lymphoma patients receiving cytostatic
drugs.
SO - Eur J Cancer B Oral Oncol 1993 Oct;29B(4):291-4
AD - Department of Oral and Maxillofacial Surgery, Helsinki University
Central Hospital, Kasarmikatu 11-13, 00140 Helsinki, Finland.
The 1-year incidence of oral mucosal lesions during cytostatic therapy
was investigated in 67 patients [34 men and 33 women (mean age 49
years)] out of 79 original patients, being treated for non-Hodgkin
lymphoma or Hodgkin's disease. The incidence of lesions during
examinations was 43.4%. Recurrent lesions were observed in 19.4% of
cases. Mean leukocyte counts were statistically significantly lower (P <
0.01) during lesion periods than before cytostatic therapy in all lesion
groups. Leukocytopenia was found in 85.4% of patients with hairy
leukoplakia-like lesions (HLL), and in 81.8% of the patients with
angular cheilitis. 5 out of 14 patients with oral ulcers (35.7%) had
episodes of septicaemia. Mean thrombocyte counts of patients in various
lesion groups were normal (< 140 x 10/1). However, low thrombocyte
counts were more statistically significant (P < 0.05), when haemorrhages
or HLL were present. Clinical candidiasis was diagnosed in 28.4% of
patients during the treatment. However, cultivation revealed that 62.3%
of salivary yeast cultures were positive. The study reported here shows
a correlation between mucosal ulcers and septicemia, and between
leukocytopenia, angular cheilitis and HLL. The disparity between
clinically diagnosed candidiasis and the occurrence of salivary yeast
counts suggests that antifungal drugs might be of prophylactic value
during cytostatic therapy.
26
UI - 11697338
AU - Fiumara P; Cabanillas F; Younes A
TI -
Interleukin-13 levels in serum from patients with Hodgkin disease and
healthy volunteers.
SO - Blood 2001 Nov 1;98(9):2877-8
27
UI - 11692557
AU - Habib G; Saliba WR
TI -
Hodgkin's lymphoma of the bone picked up by 67 Ga scintigraphy.
SO - Isr Med Assoc J 2001 Oct;3(10):778
AD - Department of Internal Medicine B, Carmel Medical Center, Rappoport
Faculty of Medicine, Technion-Israel Institute of Technology, Haifa,
Israel. gshabib62@yahoo.com
28
UI - 11696441
AU - Torlakovic E; Tierens A; Dang HD; Delabie J
TI -
The transcription factor PU.1, necessary for B-cell development is
expressed in lymphocyte predominance, but not classical Hodgkin's
disease.
SO - Am J Pathol 2001 Nov;159(5):1807-14
AD - Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway.
emina.torlakovic@labmed.uio.no
Hodgkin's disease (HD) is a lymphoproliferative disease of predominantly
B-cell origin. However, the reasons for the incomplete development of
the B-cell phenotype and lack of immunoglobulin expression in classical
HD (cHD) have not been fully explained. We examined the expression of
PU.1 in HD, an Ets-family transcription factor, which regulates the
expression of immunoglobulin and other genes that are important for
B-cell development. Immunohistochemistry for PU.1 was performed on 35
cases of cHD and 15 cases of lymphocyte predominance HD as well as 67
non-Hodgkin's lymphomas (NHL). Expression of PU.1 was studied by Western
blotting in four cHD-derived cell lines and in five NHL cell lines. We
also studied the expression of two additional B-cell transcription
factors, B-cell-specific activator protein and Oct-2. Our results show a
striking lack of PU.1 expression by neoplastic cells in cHD but not in
lymphocyte predominance HD. Our study also confirmed that
B-cell-specific activator protein but not Oct-2 is not expressed by cHD.
Western blotting showed no PU.1 protein expression in the cHD-derived
cell lines, with the exception of one cell line of putative
monocyte/histiocyte origin. The lack of PU.1 protein expression in cHD
likely contributes to the lack of immunoglobulin expression and
incomplete B-cell phenotype characteristic of the Reed-Sternberg cells
in cHD.
29
UI - 11698007
AU - Craver RD; Scheer WD; Correa H; Vehaskari VM; Yu LC
TI -
Hodgkin lymphoma in a renal transplant recipient associated with low
peripheral blood Epstein-Barr virus genome copies.
SO - Arch Pathol Lab Med 2001 Nov;125(11):1480-2
AD - Department of Pathology, Louisiana State University Medical Center, New
Orleans, LA, USA. rcrave@lsuhsc.edu
Posttransplant lymphoproliferative disorders are often accompanied by
>500 Epstein-Barr virus (EBV) genome copies/10(5) lymphocytes, and they
occur shortly after transplantation. Hodgkin lymphoma occurs rarely
after transplantation, appearing a mean of 4.2 years posttransplant, and
although Hodgkin lymphoma has strong associations with EBV, no
quantitative analysis of peripheral blood EBV genome copies has been
reported. A mixed cellularity Hodgkin lymphoma developed in a
17-year-old boy 4 years after a renal transplant. Serial EBV genome copy
numbers from blood by competitive polymerase chain reaction had been
obtained to assess for lymphoproliferative disease. Epstein-Barr virus
genome copy numbers peaked at 500 copies/10(5) lymphocytes 8 months
prior to Hodgkin lymphoma diagnosis but fell to 8 copies/10(5)
lymphocytes at diagnosis. Reliance on EBV levels greater than 500 copies
may result in delay of biopsy and diagnosis of Hodgkin disease in the
posttransplant setting.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home